• Why Attend?
  • Agenda
  • OCT Advisory Board
  • Speakers
  • Plan Your Visit
  • Event Gallery
  • 2026 Sponsors
  • Why partner?
  • Contact Us

Why Attend?

 

‘Providing a specific platform for the clinical trials community in the DACH region to develop innovative clinical operations and outsourcing strategies’

After a hugely successful 2024 conference, we are pleased to announce that the Outsourcing Clinical Trials DACH event will be returning to Zurich. This event will focus upon the operational challenges in clinical development found within Germany, Austria and Switzerland. Over two days, delegates will discuss the common challenges and trends impacting the region, including steps for defining contractual relationships and getting the maximum from external providers, incentivizing good relationships with CROs and constructing defined deadlines.

 

Why Join?

  • Focused conference for the DACH pharma market– Unlike other conferences, our event specifically focuses on the local pharma industry in Switzerland, Germany and Austria, highlighting the current challenges and exciting innovations and opportunities within the market
  • Excellent speaker line up – Senior level speakers from leading organisations such as Roche, AstraZeneca and Novartis along with exciting biotechs like Medac and Medigene
  • Great and Diverse Sessions – Our OCT DACH covers a variety of topics ranging from updated EMA Guidance to Direct to Patient and Data management innovation to CRO relationship
  • Unbeatable Networking Opportunities – Meet and network with over 150 senior industry decision makers during our dedicated networking breaks, round tables and interactive sessions

WHAT TO EXPECT FOR 2025?

Join pharma and biotech experts to discuss new trends and opportunities and learn how they optimize their clinical operations enabling you to stay ahead of the game. Find the right solution providers to partner with, allowing you to accelerate your trial timelines.

200+

Attendees

40+

Speakers

20+

Exhibitors
200+

Attendees

40+

Speakers
20+

Exhibitors

Testimonials

See What It's All About

Sponsors Include:

Back

Company Information

1MED, a Specialty MedTech and combination product solutions provider, offering end-to-end development services and digital solutions to MedTech companies across Europe.

Our offerings include preclinical and regulatory support, quality management, clinical trial management, pre and post market trial support, biometrics, medical writing and digital solutions across the clinical research continuum with a cross-functional approach.

In the past 5 years 1Med has supported 500+ different medical devices with certification and shelf life extension.

Visit 1med.net  for more information.

Company Website

To learn more, please visit our website - https://1med.net/

Next Sponsor
Back

Company Information

Syneos Health (Nasdaq:SYNH*) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together, we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit SyneosHealth.com. 

Company Website

To learn more, please visit our website - www.SyneosHealth.com

Next Sponsor
Back

Company Information

Biorce builds AI infrastructure for clinical trials. Our platform, Aika, accelerates how pharmaceutical companies, biotechs, and CROs design and execute clinical research—reducing protocol development time by at least 50% while eliminating costly amendments that delay patient access to life-saving treatments. Built on a foundation of 1 million clinical trials, Aika delivers evidence-based recommendations with complete regulatory transparency. Every decision auditable and defensible before agencies like the FDA and EMA.

Company Website

To learn more, please visit our website - https://www.biorce.com/

Next Sponsor
Back

Company Information

At Wemedoo AG, we develop advanced clinical data systems. Our unified SaaS platform, oomnia, supports all study types and phases, integrating EDC, RTSM, CTMS, eTMF, ePRO/eCOA, and eSource in one system, ensuring real-time access, streamlined processes, and successful clinical trial outcomes.

Next Sponsor
Back

Company Information

Flex Databases platform is a secure, unified and compliant system for clinical trials. Our platform consists of 13 modules that cover every aspect of clinical trials, from project startup to pharmacovigilance. We offer both single modules and a unified solution to maintain all processes – you can cover all existing software needs with only one vendor.

Company Website

To learn more, please visit our website - www.flexdatabases.com

Next Sponsor
Back

Company Information

“elderbrook solutions delivers high-impact clinical data management, biostatistics, and quality management services for life sciences companies. Our collaborative approach ensures efficiency, quality, and compliance at every stage of clinical development. We are your trusted partner for tailored solutions and expert support across biopharma, biotech, and medtech trials.”

Next Sponsor
Back

Company Information

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.

Company Website

To learn more, please visit our website - www.novotech-cro.com

Next Sponsor
Back

Company Information

Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas such as neuroscience, substance abuse, pain, tobacco harm reduction, infectious diseases and many others. CRO services include project management, data management, biostatistics, statistical programming, PK/PD analysis, medical writing, monitoring, site feasibility and management for multi-site trials.

Company Website

To learn more, please visit our website - www.drvince.com/cro/

Next Sponsor
Back

Company Information

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as at September 30, 2022.

Company Website

To learn more, please visit our website - https://www.iconplc.com/sectors/biotech

Next Sponsor
Back

Company Information

HEMEX is a European CRO supporting pharmaceutical, biotech, and MedTech SMEs with clinical development solutions. Headquartered in Basel and operating globally, we manage multinational trials. Our services include clinical operations, regulatory support, quality assurance, BA/BE and PK studies, patient recruitment, and advanced medical imaging

Company Website

To learn more, please visit our website - https://hemex.ch/

Next Sponsor
Back

Company Information

Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Company Website

To learn more, please visit our website - https://www.fortrea.com/

Next Sponsor
Back

Company Information

The PPD clinical research business of Thermo Fisher Scientific enable customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, our capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services.

Company Website

To learn more, please visit our website - https://thermofisher.com/ppd

Next Sponsor
Back

Company Information

NUVISAN is a well-established contract research organization with more than 40 years of experience in conducting early clinical development trials on healthy subjects, special populations, and patients at our own clinical site in Germany. For our Phase II and III clinical trial solutions, we can support both local and cross-region clinical trial projects in Europe and LATAM.

Coupled with our clinical trial solution, NUVISAN provides non-clinical studies, bioanalysis lab, pharmaceutical solutions, and supplies for clinical trials- all solutions are under one roof ensuring seamless support for our clients

Company Website

To learn more, please visit our website - http://www.nuvisan.com

Next Sponsor
Back

Company Information

Florence is the leading Trial Operations Platform, trusted by 65,000+ research teams worldwide. We unify sites, sponsors, and CROs in one secure system to streamline trial operations from start-up through closeout. Fully compliant with global regulatory standards, including MHRA and GDPR, Florence enables secure oversight, standardized workflows, and seamless sponsor-site collaboration—helping research organizations operate more efficiently and bring therapies to patients faster. Learn more at www.florencehc.com.

Next Sponsor
Back

Company Information

Research Grid (R.grid) specializes in AI-native automation for clinical trials. It’s safely engineered with fully traceable AI products that automate manual back-office workflows from pre-trial planning to trial close.
Working with sponsors and CROs globally, Research Grid supports more efficient, scalable trial delivery, so your team can move faster, stay compliant, and focus on what matters most.

Next Sponsor
Back

Company Information

Evestia Clinical is the specialist CRO for biotech running oncology, rare disease, and neurodegenerative trials. Your program is never a low priority for us. You get direct access to senior leaders from day one. The same team starts and finishes your trial. Your science deserves nothing less.
evestiaclinical.com

Next Sponsor
Back

Company Information

Comac Medical is focused on providing innovative and flexible solutions of the highest quality to meet pharmaceutical industry needs. Founded in 1997, we are CRO and SMO managing the full spectrum of clinical trial services from Phase I – IV across 30 European countries, the US and APAC. With applying our innovative solutions, we can ensure that the Clients’ projects are managed with the highest level of efficiency.

In 2005 Comac Medical started its state-of-the-art Clinical Research Unit for Phase I, BA/BE studies with 42 hospital beds, a highly qualified medical and operational team, a large patient/healthy volunteers database, an extensive referral physician network, and central laboratory/pharmacy services.

The company has a global reputation for excellence built over 25 years of offering tailored solutions to our Clients. To keep up to date with the latest news, follow Comac Medical on LinkedIn or

Company Website

To learn more, please visit our website - comac-medical.com

Next Sponsor

    Agenda

    • 3 Nov 2026
    • 4 Nov 2026
    Expand All

    Streams

    Stream one

    STREAM A: Outsourcing & Clinical Operations

    Stream two

    STREAM B: Data, AI & Clinical Innovation

    11:30 AM

    AI-Powered Knowledge Management in Complex Organisations: Transforming SharePoint into an Intelligent Collaboration Ecosystem

    • Demonstrating how SharePoint can evolve into an intelligent collaboration and knowledge-sharing ecosystem through AI agents and automation
    • Showcasing practical applications including automated content classification, intelligent search, chatbots, and workflow automation
    • Identifying how AI-enabled knowledge systems can improve information accessibility, collaboration, decision-making, and organisational agility while reducing inefficiencies and knowledge silos across teams

    Speakers

    Lidia Magielska
    Director, Study Management, AstraZeneca

    12 PM

    Session reserved for event sponsor

    12:30 PM

    PANEL DISCUSSION Future-Proofing Clinical Trials with AI: Will Today’s AI Strategies Survive Tomorrow’s Clinical Trial Landscape?

    • Exploring how AI can support end-to-end clinical trial delivery, from protocol authoring and risk assessment through to data analysis and reporting
    • Examining how historical trial outcomes, regulatory feedback, and operational data can be leveraged to improve planning, country selection, site strategy, and database design
    • Understanding how AI-driven connectivity across departments can break down silos and create a more integrated approach to trial execution
    • Discussing how organisations can operationalise AI strategically to future-proof clinical development processes rather than applying disconnected point solutions

    1 seat available for event sponsor

    Speakers

    Sotirios Perdikeas
    Executive Director, Head of Health Data Insights & Design, Novartis
    Stephan Theinert
    Head Clinical Affairs, FiberSense

    1 PM

    Session reserved for event sponsor

    1:30 PM

    Lunch and networking

    2:30 PM

    Building Responsible AI Systems: Lessons for Life Sciences

    • Understanding the core principles of responsible AI and how trust, transparency, governance, and human oversight enable successful AI adoption
    • Navigating evolving regulatory and ethical expectations to ensure AI systems remain compliant, secure and fit for purpose
    • Mitigating AI risks by addressing bias, data quality model validation, and continuous performance monitoring throughout the AI lifecycle
    • Scaling responsible AI across clinical development and operations to drive innovation while maintaining patient trust and regulatory confidence

    Speakers

    Marta Batlle López
    Responsible AI and GenAI Lead, Roche

    3 PM

    Session reserved for event sponsor

    3:30 PM

    LIVE DEBATE Data Hoarding or Data Sharing? Rethinking Collaboration in Clinical Research

    • Exploring the untapped potential of data sitting across academic centres, hospitals, sponsors, and research networks
    • Debating whether competitive advantage is preventing the industry from unlocking faster and more cost-effective innovation
    • Examining the operational, ethical, and commercial challenges associated with large-scale data sharing initiatives
    • Discussing whether cross-industry consortia could create shared value, reduce duplication, and accelerate clinical development for all stakeholders

    Debater 1: Eric Hajjar, Project Lead – Serious Bacterial Infections, Global Antibiotic R&D Partnership (GARDP)

    Debater 2: Available

    Speakers

    Eric Hajjar
    Project Lead – Serious Bacterial Infections, Global Antibiotic R&D Partnership (GARDP)

    4 PM

    Afternoon refreshments, networking and prize draw

    4:15 PM

    PRIZE DRAW

    Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple prizes or Amazon gift cards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!

    4:30 PM

    CASE STUDY Enhanced Pharmacovigilance Pregnancy Data Collection to Support Regulatory Requests

    • Strengthening pregnancy safety data collection to meet evolving regulatory expectations and post-marketing requirements
    • Utilising pharmacovigilance processes to improve the quality, completeness, and consistency of pregnancy data
    • Examining a real-world case study demonstrating practical approaches and considerations to enhanced pregnancy data collection and regulatory compliance
    • Leveraging enhanced pregnancy data collection to support regulatory submissions, benefit-risk assessments, and patient safety

    Speakers

    Robert Corbé
    Associate Director, Patient Safety Scientist, AstraZeneca

    5 PM

    Evidence Generation and Endpoint Strategy in Biotech Clinical Trials

    • Developing evidence generation strategies that align with regulatory expectations and clinical development goals
    • Selecting meaningful clinical and patient-centred endpoints to support efficient trial design and execution
    • Integrating innovative trial designs, biomarkers, and real-world evidence to strengthen development decisions
    • Optimising endpoint strategies to reduce development risk, accelerate approvals, and improve trial outcomes

    Speakers

    Florian Vogl
    Fractional, CMO, Stealth Mode Biotech

    5:30 PM

    Why Innovation Fails to Scale at the Pilot Stage

    • Defining clear ownership, success metrics, and decision points at every stage of implementation
    • Exploring how sponsors, CROs, and technology partners can better align expectations and timelines
    • Is the industry too risk-averse to innovate properly?
    • Identifying when to pivot, pause, or scale innovations based on measurable impact and long-term feasibility

    Speakers

    Ana Rita Delgado
    Global Medical Development Engagement Lead, Sanofi

    8 AM

    Registration and Refreshments

    8:45 AM

    Chairperson’s opening remarks

    9 AM

    KEYNOTE: What Really Changes After a $100 Million Financing Round?

    • How should clinical trial sponsors allocate resources to accelerate clinical development without compromising quality?
    • Making strategic investment decisions across people, technology, quality and partnerships
    • Deciding where to build internal capabilities versus leveraging external partners
    • Balancing speed, quality and capital efficiency while preparing for the next stage of growth

    Speakers

    Dominik Hart
    Chief Medical Officer, Granite Bio
    Sofia Ribeiro Forte
    VP, Head Clinical Operations, Granite Bio

    9:30 AM

    Session reserved for featured sponsor

    10 AM

    PANEL DISCUSSION How Shifting Geopolitical and Regulatory Dynamics Are Reshaping Clinical Trial Destinations and How to Bring the Focus Back to Europe

    • Looking at why Europe is losing competitiveness and risks falling behind in trial attractiveness and patient access despite advanced healthcare systems and strong research reputations
    • What must change for Europe to remain desirable, including initiatives shaping the future European landscape (FAST‑EU, COMBINE, EU Biotech Act)
    • Examining the rise of emerging trial destinations, from China to the Middle East, alongside the ethical responsibilities and more favourable regulatory approvals
    • Exploring the role of ISO 18969 in harmonising clinical investigation processes and supporting more efficient trial delivery across Europe

    1 seat available for event sponsor

    Speakers

    Pilar de la Rocha Mur
    VP, Head of EMEA, Global Clinical Operations, BeOne Medicines
    Simona Berardi Vilei
    Head of GCP/GVP Inspectorate, Swissmedic

    10:30 AM

    Session reserved for featured sponsor

    11 AM

    Morning refreshments and networking break

    11:30 AM

    The Clinical Development Paradox: Trial Timelines Are Becoming Increasingly Rigid, But Trial Complexity Keeps Growing

    • Why faster development timelines are colliding with increasing trial complexity
    • Understanding how accelerated pathways are reshaping expectations across sponsors, CROs and regulators
    • Assessing whether traditional operating and outsourcing models can keep pace with today's demands
    • Adapting to rolling submissions, real-time oversight and compressed development timelines
    • Building operational resilience without compromising speed, quality or compliance

    Speakers

    Maria Koutsopoulou
    SVP, Head of Global Development Operations, Merck

    12 PM

    Session reserved for event sponsor

    12:30 PM

    Site Engagement in a Competitive Trial Landscape: How Sponsors Can Become a Preferred Partner

    Speakers

    Pilar de la Rocha Mur
    VP, Head of EMEA, Global Clinical Operations, BeOne Medicines

    1 PM

    Session reserved for event sponsor

    1:30 PM

    Lunch and networking

    2:30 PM

    PATIENT ADVOCATE SPOTLIGHT Avoiding Turbulence: How Early Patient Research Partner Involvement Keeps Clinical Development on Course

    • Understanding the evidence and recommendations for meaningful Patient Research Partner (PRP) involvement in clinical research: Review the 2023 EULAR recommendations and explore why involving PRPs from the inception of a research programme can improve the relevance, feasibility and quality of clinical development.
    • Recognising the impact of early patient partnership on clinical trial success: Examine how PRP involvement can influence protocol design, patient burden, recruitment, retention, study execution and ultimately support regulatory decision-making and approval readiness.
    • Identifying practical approaches to implementation and measurement: Discuss how sponsors, CROs and research teams can operationalise PRP involvement throughout outsourced clinical development programmes, assess current levels of adoption, and measure the value and impact of patient partnership.

    Speakers

    Karen Cheng
    Patient Advocate, EULAR PARE

    3 PM

    Session reserved for event sponsor

    3:30 PM

    LIVE DEBATE Are large CRO operating models equipped to support the agility and priorities of small biotechs?

    • Navigating traditional and niche CRO models as an emerging biotech
    • Understanding the key differences between big pharma and biotech approaches to clinical trial execution and outsourcing strategy
    • Examining how niche and specialist vendors are addressing sponsor pain points with more tailored, flexible solutions
    • Identifying how sponsors and providers can better align expectations, communication models, and operational support for successful partnerships

    Debater 1: Juliet Dizon, Director, Pre-Clinical and Clinical Quality Assurance, ARTBIO

    Debater 2: Available

    Speakers

    Juliet Dizon
    Director, Pre-Clinical and Clinical Quality Assurance, ARTBIO

    4 PM

    Afternoon refreshments, networking and prize draw

    4:15 PM

    PRIZE DRAW

    Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple prizes or Amazon gift cards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!

    4:30 PM

    Streamlining Contracts and Approvals to Accelerate Site Activation for Study Start-Up

    • Optimising contracting across the clinical trial ecosystem
    • Adapting vendor oversight and management models to evolving regulatory requirements
    • Strengthening sponsor–CRO partnerships to improve accountability and execution
    • Reducing approval bottlenecks to accelerate study start-up and trial delivery

    Speakers

    Piotr Slawik
    Assistant General Counsel, Spur Therapeutics

    5 PM

    PATIENT ADVOCATE AND SITE SPOTLIGHT Cultural Change in Clinical Trial Development with a Patient and Sites Expert Panel

    Speakers

    Robina Weermeijer
    Global Clinical Trials Patient & Site Engagement Lead, Boehringer Ingelheim
    Estelle Jobson
    Patient Advocate

    5:30 PM

    CLOSING PANEL DISCUSSION The Feasibility Crisis: Are Sponsors Pushing Sites Beyond Capacity?

    • Why recruitment forecasts and feasibility assessments across the DACH region continue to miss targets despite strong research infrastructure and healthcare systems
    • How increasing study competition, protocol complexity, and limited patient availability are placing growing pressure on sites
    • The operational challenges impacting recruitment and patient access across the region
    • How sponsors, CROs, and sites can work together to create more realistic feasibility strategies and more sustainable approaches to patient recruitment and site engagement

    2 seats available for biotech/ pharma

    1 seat available for event sponsor

    Speakers

    Sabine de Ducla
    Clinical Operations Country Head – Switzerland, Roche

    6 PM

    Chair’s closing remarks

    END OF DAY 1 AND NETWORKING DRINKS

    Best 3 LinkedIn posts from day 1 with hashtag #OCT and @Outsourcing in Clinical Trials Event Series tagged will win a prize in day 2 morning’s prize draw during chair’s opening remarks. Deadline end of drinks reception day 1. You must be present to win!

    8:15 AM

    Registration and refreshments

    8:20 AM

    Chair’s opening remarks

    8:30 AM

    Interactive Speaker-Hosted Breakfast Breakout Discussions

    With drinks and refreshments, interactive breakout sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will run for 30 minutes and be led by a table moderator and will focus on a different challenge within clinical trials. Breakout discussions are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

    Discussion 1 What Types of Challenges Are Best to Be Solved with Technology and AI, and What Are the Best Ways to Operationalise?
    Discussion 2 Exploring How Evolving FDA and EMA Guidance Is Shaping the Next Phase of Global Clinical Trials
    Discussion 3 Mastering Next-Generation Outsourcing Models: Assessing Competing Strategies to Optimize Clinical Efficiency and Costs for Maximum ROI
    Discussion 4 What Sponsors Still Get Wrong About Patient-Centred Clinical Research

    9 AM

    KEYNOTE: Insights from Swissmedic Inspections: Common GCP Findings and Practical Lessons for Sponsors and CROs

    • Key recurring GCP findings identified in recent Swissmedic inspections
    • A Swissmedic perspective on ICH E6(R3), Real-Time Monitoring and evolving regulatory expectations
    • Common gaps in oversight, documentation, and trial master file (TMF) management
    • Frequent issues in vendor/CRO oversight and delegated responsibilities
    • Practical recommendations to strengthen inspection readiness and quality systems

    Speakers

    Simona Berardi Vilei
    Head of GCP/GVP Inspectorate, Swissmedic

    9:30 AM

    Session reserved for event sponsor

    10 AM

    PANEL DISCUSSION Preventing the Preventable: Why Patients Still Walk Away from Clinical Trials

    • Tackling the hidden drivers of patient dropout
    • Understanding how participant-focused engagement strategies can improve recruitment, trust, and long-term retention
    • When is enough enough, and how much is excessive data collection driving the patients away?
    • Identifying why participants disengage during studies and what sponsors and sites can do proactively to reduce attrition

    2 seats available for biotech/ pharma

    1 seat available for event sponsor

    Speakers

    Karen Cheng
    Patient Advocate, EULAR PARE

    10:30 AM

    Morning refreshments and networking break

    11 AM

    Are We Designing the Right Clinical Trials or Just the Safest Ones?

    • Have clinical trials become over-engineered for predictability at the expense of speed, feasibility, and patient access
    • Are protocols optimised for regulatory comfort rather than real-world execution and site capacity
    • Is clinical trial eligibility criteria too stringent?
    • Can adaptive designs, simulation, and AI shift trial design from risk avoidance to smarter decision-making

    Speakers

    Daniel McVeigh
    Director, Clinical Operations, Alexion Pharma

    11:30 AM

    Session reserved for event sponsor

    12 PM

    NEW FOR 2026! INDUSTRY HOT TAKES

    1 stage, a variety of rapid-fire opinions, bold predictions and myth-busting from experts across the industry. Audience members will vote, agree or disagree, on each hot take! There’ll be a chance for the audience to pose some questions to the panel too.

    The panel will answer the following:

    • Biggest mistake in clinical trials today
    • One thing pharma should stop doing
    • One prediction for 2030
    • What’s overhyped and what’s worth the hype
    • What vendors misunderstand
    • Where trials fail most often
    • Biggest recruitment mistake
    • Hot takes from the audience

    2 seats available for biotech/ pharma

    1 seat available for event sponsor

    Speakers

    Eric Hajjar
    Project Lead – Serious Bacterial Infections, Global Antibiotic R&D Partnership (GARDP)

    12:30 PM

    Session reserved for event sponsor

    1 PM

    Lunch and networking

    2 PM

    Rethinking How Patients Contribute to Drug Development: How Servier Embed Patient Engagement Across R&D

    Speakers

    Laura Risueño Ayerbe
    Global Patient Affairs, Patient Engagement R&D, Servier

    2:30 PM

    Session reserved for event sponsor

    3 PM

    Afternoon refreshments, networking and prize draw

    3:15 PM

    PRIZE DRAW

    Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple prizes or Amazon gift cards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!

    3:30 PM

    Biosimilar Development: New FDA and EMA Regulations Are a Paradigm Shift After 20 Years of Biosimilars

    • Reducing development costs through leaner clinical strategies
    • Navigating evolving regulatory expectations for biosimilars in Europe and globally
    • Understanding how outsourcing models differ for biosimilar programs versus innovative therapies

    Speakers

    Karsten Roth
    Senior Director Clinical Research and Development, Polpharma Biologics

    4 PM

    CLOSING KEYNOTE – EUPATI Switzerland: Advancing Meaningful Patient Engagement in Healthcare R&D

    • Embedding patients as equal partners across the medicines development lifecycle
    • Building trust through education, transparency and collaborative decision-making
    • Strengthening patient engagement to improve clinical research and regulatory decisions
    • EUPATI case study: Practical examples of how meaningful patient involvement creates lasting impact

    Speakers

    Ivo Schauwecker
    President of EUPATI Switzerland and Head of Research Ethics at ETH Zürich

    4:30 PM

    END OF CONFERENCE

    Speakers

    Select a speaker to learn more

    Back
    Daniel McVeigh
    Director, Clinical Operations, Alexion

    A Clinical Research Professional with over 13 years’ experience across various settings such as Site, CRO, Small Biotech and Pharma. Expertise in various therapeutic areas from Oncology and Rare/Orphan Disease. Experience from early phase first in human to late phase and Nov Intervention RWE generation and Registries. Focused on Clinical Operations excellence and process improvements for the benefit of the patients we serve. Currently Director, CPL at Alexion, AZ Rare Disease leading a Cross Functional clinical team.

    Next speaker
    Back
    Juliet Dizon
    Director, Pre-Clinical and Clinical Quality Assurance, ARTBIO

    I am a Clinical Research professional with more than 20 years of combined experience across the pharmaceutical, biotechnology, and medical devices industries. My background includes 17 years as a Quality Professional in Switzerland and 3 years in Singapore where I managed clinical monitoring and operations, directly overseen drug-device combination trials across 13 Asia-Pacific countries including Japan, Australia/New Zealand, China, Japan, South Korea, India, and others.

    I am a highly skilled Quality Professional with focus on Quality Assurance, end to end Quality Strategy, Risk Management and Compliance. Recognized for work ethics and passionate leadership. Strategic and with extensive experience driving global pharmaceutical development and regulatory success. Expert in integrating end-to-end quality principles across cross-functional R&D programs and implementing Quality by Design (QbD) aided by data analytics.

    Specializing in GCP, GLP, GMP, Pharmacovigilance (GVP), and Computerized System Validation (CSV). Led global audits, inspection readiness, and Health Authority inspections for high-priority NDAs. Expertise in Risk-Based Quality Management, Quality Strategy, Quality Narratives and regulatory compliance across major global health authorities.

    An empathetic People Leader who champions growth and development of team members to help them reach their full potentials, mentored cross functional teams and coached direct reports globally, recognised for stakeholder engagement and effective collaboration across diverse, multi-cultural environment in both big pharma and start-up biotechnology environments.

    Session Details:

    LIVE DEBATE Are large CRO operating models equipped to support the agility and priorities of small biotechs?

    2026-11-03, 3:30 PM

    View In Agenda
    Next speaker
    Back
    Lidia Magielska
    Director, Study Management, AstraZeneca

    Global clinical trials, teams leader with extensive experience in pharmaceutical business. Innovative, agile, proactive mindset with hands on experience in leading multiply projects, teams and people development. Cross department knowledge with business acumen. Project management of global clinical trials, site management and monitoring, CRO management. Line management, coaching, leadership. Pharmaceutical sales & marketing with projects delivery for generic and innovative products with proven achievements track. Working experience in clinical trial management in China.
    Passionate about medicines development, strategic management and multicultural environment.
    Interested in new solutions and innovation in project and program management in clinical trials with a global scope.

    Session Details:

    AI-Powered Knowledge Management in Complex Organisations: Transforming SharePoint into an Intelligent Collaboration Ecosystem

    2026-11-03, 11:30 AM

    View In Agenda
    Next speaker
    Back
    Robert Corbé
    Associate Director, Patient Safety Scientist, AstraZeneca
    Next speaker
    Back
    Pilar de la Rocha Mur
    VP, Head of EMEA, Global Clinical Operations, BeOne Medicines

    Global Drug Development Executive | Board Member | Founder
    Strategic Leader in Oncology and Global Clinical Operations.
    22+ Years Building and Governing High-Impact Teams Across 6 Continents
    Driving Innovation, Scale, and Long-Term Enterprise Value

    Session Details:

    Site Engagement in a Competitive Trial Landscape: How Sponsors Can Become a Preferred Partner

    2026-11-03, 12:30 PM

    Session Details:

    PANEL DISCUSSION How Shifting Geopolitical and Regulatory Dynamics Are Reshaping Clinical Trial Destinations and How to Bring the Focus Back to Europe

    2026-11-03, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Robina Weermeijer
    Global Clinical Trials Patient & Site Engagement Lead, Boehringer Ingelheim

    Patient & Site Engagement Lead focused on representation in clinical trials at Boehringer Ingelheim, passionate about transforming healthcare. With 10+ years of experience in the pharmaceutical industry, I connect and collaborate with patients & healthcare professionals worldwide, to help make our clinical trials more accesible. Let's work together to make clinical research more inclusive!

    Session Details:

    PATIENT ADVOCATE AND SITE SPOTLIGHT Cultural Change in Clinical Trial Development with a Patient and Sites Expert Panel

    2026-11-03, 5:00 PM

    View In Agenda
    Next speaker
    Back
    Stephan Theinert
    Head Clinical Affairs, FiberSense

    Stephan Theinert holds a Ph.D.of the Charité- University Medicine Berlin, Germany in immunology since 2007. He studied biology at the Humboldt-University in Berlin, Germany with an emphasis on microbiology, genetic and biochemistry. In 2006 he joined the PAREXEL GmbH in Berlin, Germany as a project manager clinical phase I. In 2008 he joined the Momentum Pharma Services GmbH in Hamburg, Germany as a manager business development. In 2009 he became director business development. Since end of 2009 he, as Head Clinical Affairs at the EyeSense GmbH, is mainly responsible for the clinical studies inlc. parts of regulatory and medical affairs.

    Session Details:

    PANEL DISCUSSION Future-Proofing Clinical Trials with AI: Will Today’s AI Strategies Survive Tomorrow’s Clinical Trial Landscape?

    2026-11-03, 12:30 PM

    View In Agenda
    Next speaker
    Back
    Eric Hajjar
    Former Associate Director, Global Medical Research Operations, Biogen
    Next speaker
    Back
    Eric Hajjar
    Project Lead – Serious Bacterial Infections, Global Antibiotic R&D Partnership (GARDP)

    Session Details:

    LIVE DEBATE Data Hoarding or Data Sharing? Rethinking Collaboration in Clinical Research

    2026-11-03, 3:30 PM

    Session Details:

    NEW FOR 2026! INDUSTRY HOT TAKES

    2026-11-04, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Tina Taylor
    Vice President of Disease Intelligence and Epidemiology, GlobalData

    With over 15 years of experience at the forefront of market intelligence, currently serving as Vice President of Disease Intelligence and Epidemiology at GlobalData Healthcare. My expertise spans leadership, data, disease and competitive analytics, market research, people and project management. I am focused on empowering teams to deliver actionable insights in pharma and biotech, and dedicated to driving data-driven decisions that align with organizational goals. Known for collaborative leadership and a commitment to fostering impactful outcomes through strategic analysis and innovative disease intelligence solutions. Excited to be part of delivering cutting-edge market research and intelligence.

    Next speaker
    Back
    Dominik Hart
    Chief Medical Officer, Granite Bio

    Physician Scientist with Big-Pharma & Biotech Drug Development expertise in Immunology/IBD/Cell Depletion/CAR-T/TCE/Derm/T2-Inflammation/Respiratory/Fibrosis/Renal. Advanced multiple assets from pre-clinic into clinic & from Ph1 into Ph2/3.

    CMO of GRANITE-BIO: Clinical-Stage I&I Biotech developing novel Immune-Cell Depletion antibodies. FIC Innate/Myeloid immune reset (CCR2-monocyte depleting mAb Minokitug). Biomarker-guided adaptive IBD Monolith trial. NOVARTIS Option-to-Acquire deal. www.granitebio.com

    Former CMO of QUELL Therapeutics: CAR-T/Treg Therapies for Autoimmune Diseases (Liver, Kidney, Tx, T1D, IBD). AstraZeneca partnership deal. www.quell-tx.com

    Former Immunology/Translational Medicine Leadership roles at Roche & Novartis. Involved in various Global Drug Development programs (Ph1/2/3: B-cell depleters, ianalumab, secukinumab, iptacopan, canakinumab, NLRP3, remibrutinib, tocilizumab, JAKi/filgotinib)

    MERCK Immunology advisory board member

    AI-based Drug Development project RN.AI with Fabian Theis (Helmholtz)

    Session Details:

    KEYNOTE: What Really Changes After a $100 Million Financing Round?

    2026-11-03, 9:00 AM

    View In Agenda
    Next speaker
    Back
    Sofia Ribeiro Forte
    VP, Head Clinical Operations, Granite Bio

    Session Details:

    KEYNOTE: What Really Changes After a $100 Million Financing Round?

    2026-11-03, 9:00 AM

    View In Agenda
    Next speaker
    Back
    Maria Koutsopoulou
    SVP, Head of Global Development Operations, Merck

    Session Details:

    The Clinical Development Paradox: Trial Timelines Are Becoming Increasingly Rigid, But Trial Complexity Keeps Growing

    2026-11-03, 11:30 AM

    View In Agenda
    Next speaker
    Back
    Sotirios Perdikeas
    Executive Director, Head of Health Data Insights & Design, Novartis

    I am an enterprise data, AI and digital transformation leader in pharma R&D, currently heading Data & Analytics in Clinical Operations at Novartis, with a focus on strengthening decision quality at scale by integrating trusted data, AI-enabled capabilities and human judgment.

    With over 20 years of experience at the intersection of science, technology and business, I have led global teams and enterprise programs across research, clinical development, informatics and finance. My work focuses on translating complex data, digital and AI opportunities into scalable capabilities, trusted decisions and measurable business impact.

    Across Roche and Novartis, I have built and scaled AI-driven and analytics enabled capabilities supporting critical decisions across the drug development lifecycle, including study planning, protocol feasibility and design, predictive site selection, competitive intelligence and benchmarking, performance modelling and simulation, operational risk management and intelligent summarization of clinical content. These capabilities have improved decision speed, consistency, resource optimization and portfolio execution across therapeutic areas.

    I bring a systems perspective to enterprise transformation, combining pharma R&D domain knowledge, technology depth, data and AI strategy, product thinking, governance and change leadership. My leadership focus is on building future ready teams and operating models that enable organizations to move from experimentation to trusted, adopted and value-generating capabilities at scale.

    Session Details:

    PANEL DISCUSSION Future-Proofing Clinical Trials with AI: Will Today’s AI Strategies Survive Tomorrow’s Clinical Trial Landscape?

    2026-11-03, 12:30 PM

    View In Agenda
    Next speaker
    Back
    Estelle Jobson
    Patient Advocate

    Member of Boehringer Ingelheim's Global Representivity Board, 2024-2025

    • EUPATI Fellow / Alumna, trained patient expert, patient peer reviewer for the British Medical Journal, lay summary editor, and more
    • Founding patient member of Partner REC (Partenariat en Recherche Clinique) working group on patient and public involvement in research at the Geneva University Hospitals (HUG), in French
    • Author with successful marketing, paperback and e-book sales for Kindle
    • Member of IMI pool of patient experts and patient representative expert within Patients Active in Research and Dialogues for an Improved Generation of Medicines (IMI-PARADIGM)

    Session Details:

    PATIENT ADVOCATE AND SITE SPOTLIGHT Cultural Change in Clinical Trial Development with a Patient and Sites Expert Panel

    2026-11-03, 5:00 PM

    View In Agenda
    Next speaker
    Back
    Karen Cheng
    Patient Advocate, EULAR PARE

    My career began at the patient’s bedside — where science meets humanity and every decision carries real consequence. Then came the most profound life lesson of all: becoming the patient myself. That experience grounded me — both as a provider and a receiver of care — and continues to shape everything I do. Every diagnosis carries a story, every therapy holds a promise, and every decision can change a life.

    My passion lies in rare diseases, where patients often wait the longest for answers, and where scientific excellence and empathy must go hand in hand. I’ve had the privilege of collaborating with brilliant minds across the globe — physicians, researchers, patients, and policymakers — and I’ve seen firsthand that true progress happens when we connect ideas across borders, disciplines, and perspectives.

    My experience in medical affairs, clinical development, education, patient partnership, product management, operations, and commercial strategy, was built by complex launches across geographies, challenges in evidence generation and nurturing cross-functional alliances to strengthen and advance both medical understanding and patient access to appropriate care.

    My international mindset was developed from living and working in seven countries across three continents. I thrive in diverse, matrix environments where creativity, compassion, and collaboration drive performance. I’m energized by people, inspired by purpose, and committed to advancing patient care through thoughtful leadership, integrity, and innovation.

    My mission is simple yet profound: to bridge patient perspectives, clinical insights, and corporate strategy to accelerate better solutions for patients. Every project, product, and partnership is an opportunity to improve a life — and breakthroughs mean nothing unless it reaches the people who need it most. To me, leadership in rare diseases is not a title, but a responsibility — to inspire, to connect, and to act with purpose.

    Session Details:

    PATIENT ADVOCATE SPOTLIGHT Avoiding Turbulence: How Early Patient Research Partner Involvement Keeps Clinical Development on Course

    2026-11-03, 2:30 PM

    Session Details:

    PANEL DISCUSSION Preventing the Preventable: Why Patients Still Walk Away from Clinical Trials

    2026-11-04, 10:00 AM

    View In Agenda
    Next speaker
    Back
    Ivo Schauwecker
    President of EUPATI Switzerland and Head of Research Ethics at ETH Zürich

    Team oriented leadership, reliable, enthusiastic towards new challenges, result-oriented, fair, good communicator and motivator, excellent project manager – ready to take risks and propose unconventional solutions.

    I am eager to take over responsibility in my positions to move tasks to successful completion. To lead in a strongly team-oriented business environment is my highest motivator. Teaching and imparting knowledge is a passion. To make patient and persons concerned involvement in human research happen is a mission.

    Session Details:

    CLOSING KEYNOTE – EUPATI Switzerland: Advancing Meaningful Patient Engagement in Healthcare R&D

    2026-11-04, 4:00 PM

    View In Agenda
    Next speaker
    Back
    Karsten Roth
    Senior Director Clinical Research and Development, Polpharma Biologics

    Pharmaceutical professional with more than 27 years of experience in the pharmaceutical industry, having held various international leading positions with focus on clinical development and medical affairs across several therapeutic areas. More than 17 years experience in Biosimilar development including:
    - Successful development up to approval several Biosimilars in the EU and US
    - Presentation at EMA-, FDA- and PMDA meetings of various type
    - Set up of quality management systems, including SOP implementation

    Serves as Vice-Chair at the Biosimilars Medicines Group at Medicines for Europe

    Holds a Ph.D. in Biochemistry, a postgraduate Diploma in Pharmaceutical Medicine, and a Masters in Project Management from the George Washington University.

    Session Details:

    Biosimilar Development: New FDA and EMA Regulations Are a Paradigm Shift After 20 Years of Biosimilars

    2026-11-04, 3:30 PM

    View In Agenda
    Next speaker
    Back
    Marta Batlle López
    Responsible AI and GenAI Lead, Roche

    Leading the scaling and development of trustworthy GenAI solutions at Roche for the benefit of worldwide patients. As Responsible AI and AI Governance Lead at Roche Digital Technologies, I have deep experience designing and operationalizing AI risk, ethics & governance frameworks in healthcare.

    •Proven track record implementing Enterprise-scale Responsible AI risk controls, technical guardrails and leading high-impact initiatives in partnership with Legal, Security, Ethics and Corporate AI strategy.
    •Experienced in AI risk mitigation, bias mitigation and privacy-preserving technologies, building the foundations for ethical AI innovation.
    •In my previous role as GenAI Product Owner, I led the development of large-scale customer-facing solutions

    Session Details:

    Building Responsible AI Systems: Lessons for Life Sciences

    2026-11-03, 2:30 PM

    View In Agenda
    Next speaker
    Back
    Sabine de Ducla
    Clinical Operations Country Head – Switzerland, Roche

    Clinical studies expert and people leader with >26 years of experience in both Pharmaceutical Industry and Academic Research Organization within Operations, Medical Affairs and Global Development as well as within Headquarter and affiliate organizations. Expertise across the product lifecycle: clinical trial design, trial conduct and read-out, health authority interactions, medical affairs strategic/scientific planning and execution – Cross-functional/matrix leadership and people management responsibilities, including leadership for self-organized and empowered teams and collaboration with a number of multicultural internal and external stakeholders – Empathetic and creative mindset with passion for developing, empowering, coaching and mentoring others – always keeping the patients at the center.

    Session Details:

    CLOSING PANEL DISCUSSION The Feasibility Crisis: Are Sponsors Pushing Sites Beyond Capacity?

    2026-11-03, 5:30 PM

    View In Agenda
    Next speaker
    Back
    Ana Rita Delgado
    Global Medical Development Engagement Lead, Sanofi

    Session Details:

    Why Innovation Fails to Scale at the Pilot Stage

    2026-11-03, 5:30 PM

    View In Agenda
    Next speaker
    Back
    Laura Risueño Ayerbe
    Global Patient Affairs, Patient Engagement R&D, Servier

    Pharmaceutical professional with a strong background in preclinical research and a strategic focus on patient engagement. I have experience across the drug development, from early-stage research to patient-centered initiatives, allowing me to bridge the gap between science and real-world healthcare needs. My expertise includes executing preclinical studies, interpreting complex scientific data, and translating research insights into meaningful outcomes.

    In recent years, I have shifted my focus toward patient engagement, working to integrate the patient voice into drug development processes. I am passionate about fostering collaboration between researchers, healthcare providers, and patients to ensure that treatments are not only scientifically sound but also aligned with patient needs and experiences. My ability to navigate both the scientific and human aspects of pharmaceutical development enables me to contribute to innovate.

    Session Details:

    Rethinking How Patients Contribute to Drug Development: How Servier Embed Patient Engagement Across R&D

    2026-11-04, 2:00 PM

    View In Agenda
    Next speaker
    Back
    Piotr Slawik
    Assistant General Counsel, Spur Therapeutics

    Internationally experienced in-house lawyer specialised in pharmaceutical law with substantial expertise and focus on the startup, conduct and legal compliance of research and development activities. Subject matter expert in full scope of contracts relating to clinical trials, informed consent forms, ethics and regulatory processess and data privacy aspects of clinical trials.

    Session Details:

    Streamlining Contracts and Approvals to Accelerate Site Activation for Study Start-Up

    2026-11-03, 4:30 PM

    View In Agenda
    Next speaker
    Back
    Florian Vogl
    Fractional, CMO, Stealth Mode Biotech

    Session Details:

    Evidence Generation and Endpoint Strategy in Biotech Clinical Trials

    2026-11-03, 5:00 PM

    View In Agenda
    Next speaker
    Back
    Simona Berardi Vilei
    Head of GCP/GVP Inspectorate, Swissmedic

    Experienced Head Of Project Management with a demonstrated history of working in the research industry. Skilled in Business Planning, Customer Acquisition, Medical Devices, Communication, and Oncology. Strong healthcare services professional with a Diploma of advanced studies in Pharmaceutical Medicine (DAS) focused in ECPM from Universität Basel.

    Session Details:

    PANEL DISCUSSION How Shifting Geopolitical and Regulatory Dynamics Are Reshaping Clinical Trial Destinations and How to Bring the Focus Back to Europe

    2026-11-03, 10:00 AM

    Session Details:

    KEYNOTE: Insights from Swissmedic Inspections: Common GCP Findings and Practical Lessons for Sponsors and CROs

    2026-11-04, 9:00 AM

    View In Agenda
    Next speaker

    OCT Advisory Board

    Select a member to learn more

    Back
    Dr Alison McMorn
    Head of Clinical Strategy and Development, LifeArc

    Dr. McMorn is an experienced clinical development researcher with over 25 years of industry experience and has a strong focus in CNS and paediatric drug development. She has worked for both Pharmaceutical Companies and Contract Research Organisations including holding positions at SAR Monitoring Services Ltd, Mundipharma International Ltd and Shire Development Inc. Starting her career at SAR as a Clinical Research Associate (CRA) she subsequently moved to Mundipharma where she was responsible for initiating the first paediatric clinical research program for the company. At Shire Dr. McMorn led, planned and managed global paediatric and adult clinical development programs for a wide variety of indications including psychiatry, pain, gastrointestinal and hepatology across all phases of development (Phase 0 to Phase 4). In addition she was responsible for harmonizing Clinical Trial Administrator (CTA) working practices across all regions for the company. In 2015 Dr. McMorn joined AMO Pharma Ltd, a virtual pharmaceutical company focused predominantly on paediatric neurodevelopmental rare diseases, as VP of Clinical Development. She holds an undergraduate degree in Pharmacology and a PhD in Psychology from the University of Leeds, UK.

    Next
    Back
    Behtash Bahador
    Senior Director, Community Engagement & Partnerships, Center for Information & Study on Clinical Research Participation (CISCRP)

    Behtash Bahador is the Senior Director of Community Engagement & Partnerships at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.

    Next
    Back
    Kathleen Cohen
    Vice President, Clinical Development, Marinus Pharmaceuticals

    Kathleen Frenia Cohen is Vice President and Head of Clinical Development Operations at Marinus Pharmaceuticals.  Prior to joining Marinus, she spent 20+ years at PRA Health Sciences in a variety of project management and operational oversite roles. Kathleen graduated from the University of the Science in Philadelphia with a PharmD and completed a post-doctoral fellowship in Pharmacoeconomics and Outcomes Research from Rutgers College of Pharmacy. Kathleen resides in Media, PA.

    Next
    Back
    Aditya Kotta
    VP Business Development, Novotech

    Aditya Kotta is the VP of Business Development for Novotech. He has been with the company since 2018. He has 14 years of experience in the clinical trial industry, working in both Clinical Operations and Business Development. He holds degrees in Biomedical Engineering from Johns Hopkins University and Medical Science from Boston University.

    Next
    Back
    Martin Rodriguez
    Consumer Safety & Evidence Global Quality & Excellence Head, Opella

    Senior executive Leader in Life Science (Biochemist) and Lean/Six Sigma Green-belt certified, with more than 20 year of experience in clinical operations, Operational Excellence (i.e., operational strategy, performance management, process optimization, risk management, Quality-by-Design and team performance), clinical quality, and Service Providers / Outsourcing management.

    I developed, reengineered, automated, and optimized business processes with a risk-based and approach to produce high quality outputs and to ensure regulatory compliance. I led the development, implementation and monitoring of different operational and quality strategies and models including Outsourcing as well as new/ innovative clinical capabilities to fulfill consumers/ patients needs .

    Next
    Back
    Rosalie Filling
    Vice President, Senior Global Head R&D Operations, Keenova

    In her over 25 years of experience, Rosalie “Rosie” Filling has transformed R&D operations in every company she has worked for, developing clear-cut strategies to help advance clinical trials with high-quality operational execution and scientific excellence.

     

    Rosie is the Vice President, Senior Global Head R&D Operations Endo International plc. She is part of the global R&D leadership team and is charged with the coordination and implementation of clinical development strategies for the company’s research and development. She provides strategic direction and oversight of the R&D Operations team, which includes clinical operations, data management, biostatistics, medical writing, clinical supplies, trial master file/inspection readiness and business operations. This integrated team handles the execution of all aspects related to Endo’s clinical trials. Endo has active research and development programs in men’s health, orthopedics, and endocrinology. Beyond these therapeutic areas, the company also has focused development in the areas of sterile injectables and complex generic products.

     

    Rosie’s main focus at all times is on the end users—the patients. Bringing new and, at times, life-saving medications to patients drives Rosie’s sense of purpose.

     

    Rosie joined Endo from Lupin Pharmaceuticals in Blue Bell, PA where she was Senior Director, Head of Clinical Operations, and built the clinical operations organization to support the US and Global R&D Organization. Prior to Lupin, Rosie spent nearly five years at Teva in Frazer, PA where she was the US site head of Clinical Operations and was responsible for the successful delivery of Inhalation, Women’s Health, and Cardiovascular clinical trials. Earlier in her career, Rosie held various roles at Eisai, MGI Pharma and PPD.

     

    Rosie earned her B.S. in Biology with a minor in Chemistry from the University of Pittsburgh.

    Next
    Back
    Edwin van Vulpen
    Executive Director and Head of Clinical Business Development Euro-Asia
    Next

    Plan Your Visit

    Basel Marriott Hotel Messeplatz 25 Basel, Switzerland, 4058

    Book Your Stay

    Accommodation

    Arena International Events Group “(Arena”) is aware of numerous third-party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings, events attendee lists and selling unsolicited services. It is unclear whether the agencies in question are in possession of such information, or whether they intend to scam unsuspecting customers. Whilst Arena International Events Group pursues such third-party companies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third-party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group..

    2026 Sponsors

    Select a sponsor to learn more

    FEATURED SPONSORS

    SESSION SPONSORS

    Technology Showcase

    Prize Draw Sponsor

    EXHIBITORS

    Co Sponsor

    Why partner?

     

    Contact us to become a partner

    Partnership Opportunities

    We work with you to design a bespoke package to meet your business needs, where you could:

    • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
    • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
      Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
    • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

    Event reach

    • 200+ attendees each year
    • 80% attendees C-suite level

     

    Take a look at our current sponsors

    Become A Media Partner

    WHAT TO EXPECT FOR 2025

    Join pharma and biotech experts to discuss new trends and opportunities and learn how they optimize their clinical operations enabling you to stay ahead of the game.   Find the right solution providers to partner with, allowing you to accelerate your trial timelines.

    See What It's All About

    Enquiry

    Contact Us

    SPONSORSHIP ENQUIRIES

    Alex Purnell

    Senior Sponsorship Manager

    +44 20 4540 7786

    SPEAKER & MARKETING ENQUIRIES

    Ralitsa Pashkuleva

    Conference Producer

    +44 20 7661 7976

    DELEGATE ENQUIRIES

    Sunny Saikia

    VIP Delegate Manager

    SPONSORSHIP ENQUIRIES

    Senior Sponsorship Manager

    Alex Purnell


    +44 20 4540 7786

    SPEAKER & MARKETING ENQUIRIES

    Conference Producer

    Ralitsa Pashkuleva


    +44 20 7661 7976

    DELEGATE ENQUIRIES

    VIP Delegate Manager

    Sunny Saikia